OptiNose (OPTN) Prices 25M Share Offering at $1.60/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Optinose (OPTN) PT Lowered to $9 at BMO Capital
November 17, 2021 9:08 AM ESTBMO Capital analyst Gary Nachman lowered the price target on Optinose (NASDAQ: OPTN) to $9.00 (from $16.00) while maintaining an Outperform rating.
The analyst commented, "3Q Xhance revenue was slightly below and 2021 guidance lowered given continued COVID-19 headwinds impacting sales access and Rx volumes (though... More
After-Hours Stock Movers 11/15: (AXON) (RMO) (RPRX) Higher; (BODY) (OPTN) (CLOV) Lower (more...)
November 15, 2021 6:02 PM ESTAfter-Hours Stock Movers:
Beachbody Company (NYSE: BODY) 21% LOWER; reported Q3 EPS of ($0.13), $0.02 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $208.1 million versus the consensus estimate of $246.93 million. Beachbody Company sees FY2021 revenue of $820-830 million, versus the consensus of $964 million.
Axon Enterprise, Inc. (NASDAQ: AXON) 19% HIGHER; reported revenue growth of 39% to $232 million, and GAAP net income of $49 million, which supported Adjusted EBITDA of $51 million, representing a 22% margin. Net income was favorably... More
OptiNose (OPTN) Announces Proposed Public Offering of Common Stock
November 15, 2021 5:41 PM ESTOptinose (NASDAQ: OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All shares of... More
